The rationale of the combination could be found in preclinical studies, in which bevacizumab showed to enhance PD1/PD-L1 efficacy by reversing VEGF-mediated immunosuppression and by promoting tumor T-cell infiltration [59]. Here, VEGFA is linked to neoplasm.